BioSpace News Archive

Mabwell Announces the NMPA Approval of Novel Trop-2 ADC (9MW2921) for IND

Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its clinical trial application of 9MW2921 for advanced solid tumor was approved by the National Medical Products Administration (NMPA).

July 18, 2023
·
6 min read
Pharm Country

HNL Lab Medicine Announces Groundbreaking Digital Pathology Investment

HNL Lab Medicine, a leading clinical diagnostics laboratory, is pleased to announce an investment in a new digital pathology initiative.

July 18, 2023
·
2 min read
Pharm Country

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - July 18, 2023

PTC Therapeutics, Inc. announced that on July 13, 2023, the company approved non-statutory stock options to purchase an aggregate of 66,380 shares of its common stock and 30,685 restricted stock units, each representing the right to receive one share of its common stock upon vesting, to 11 new employees.

July 18, 2023
·
2 min read
Biotech Bay

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - July 18, 2023

Ultragenyx Pharmaceutical Inc. reported the grant of 36,300 restricted stock units of the company’s common stock to 21 newly hired non-executive officers of the company.

July 18, 2023
·
1 min read
BioCapital

Acumen Announces Pricing of Upsized $130 Million Public Offering

Acumen Pharmaceuticals, Inc. (“Acumen”) (NASDAQ: ABOS) today announced the pricing of an upsized underwritten public offering of 16,774,193 shares of its common stock at a price to the public of $7.75 per share.

July 18, 2023
·
4 min read
Biophytis and SEQENS Sign a Partnership to Produce Sarconeos (BIO101) Active Compound

Biophytis SA announced the conclusion of a master agreement for the production of the active compound in Sarconeos, Biophytis’ main drug candidate developed for three indications: severe forms of Covid-19, sarcopenia and Duchenne muscular dystrophy.

July 18, 2023
·
5 min read
Business

Orexo Q2 2023 Interim Report

EBITDA of SEK 5.6 m (-32.5), EBITDA excluding legal costs and costs for non-repeating clinical trials, SEK 30.3 m (11.4)

July 18, 2023
·
3 min read
Notice of Extraordinary General Meeting in Swedish Orphan Biovitrum AB (publ)

The shareholders in Swedish Orphan Biovitrum AB Reg. No. 556038-9321, are hereby summoned to the Extraordinary General Meeting, to be held on Tuesday, 15 August 2023 at 10.00 at the offices of Mannheimer Swartling Advokatbyrå, Norrlandsgatan 21, Stockholm, Sweden.

July 18, 2023
·
12 min read
Business

Mainz Biomed Announces Collaboration with Fugene Genetics in Israel

Mainz Biomed NV, a molecular genetics diagnostic company specializing in the early detection of cancer, announces its commercial partnership for ColoAlert with Fugene Genetics, a renowned genetic testing service provider based in Israel.

July 18, 2023
·
7 min read
BioCapital

IGC Pharma, Inc. Presenting 6 Posters on the Positive Impact of IGC-AD1 on Neuropsychiatric Symptoms in Dementia at the 2023 Alzheimer’s Association International Conference

IGC Pharma, Inc. announced that it is presenting 6 in-person posters highlighting data from its Phase 1 clinical trials investigating the Company’s lead therapeutic candidate, IGC-AD1, at the Alzheimer’s Association International Conference being held July 16-20, 2023, in Amsterdam, Netherlands.

July 18, 2023
·
9 min read